Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer

Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Conditions:   Clear Cell Renal Cell Carcinoma;   Kidney Cancer;   Advanced Renal Cell Carcinoma
Interventions:   Drug: 177Lu-labeled-girentuximab;   Drug: Nivolumab;   Diagnostic Test: 89Zr-girentuximab PET/CT;   Diagnostic Test: 177Lu whole body (WB) planar and SPECT/CT scans
Sponsor:   Memorial Sloan Kettering Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 18, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments